Similar articles

• Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.

  Koh C, Heller T. Koh C, et al. Aliment Pharmacol Ther. 2015 Mar;41(6):595-6. doi: 10.1111/apt.13079. Aliment Pharmacol Ther. 2015. PMID: 25659215 No abstract available.
• Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.

  Ouzan D, Pénaranda G, Joly H, Halfon P. Ouzan D, et al. J Hepatol. 2013 Jun;58(6):1258-9. doi: 10.1016/j.jhep.2012.12.019. Epub 2013 Jan 11. J Hepatol. 2013. PMID: 23318602 No abstract available.
• Long-term therapy of chronic delta hepatitis with peginterferon alfa.

  Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, McBurney R, Schmid P, Albrecht J, Kleiner DE, Ghany MG, Liang TJ, Hoofnagle JH. Heller T, et al. Aliment Pharmacol Ther. 2014 Jul;40(1):93-104. doi: 10.1111/apt.12788. Epub 2014 May 11. Aliment Pharmacol Ther. 2014. PMID: 24815494 Free PMC article. Clinical Trial.
• Current management of delta hepatitis.

  Rizzetto M. Rizzetto M. Liver Int. 2013 Feb;33 Suppl 1:195-7. doi: 10.1111/liv.12058. Liver Int. 2013. PMID: 23286865 Review.
• [Quantification of hepatitis B virus HBsAg: clinical implications].

  Buti M, Rodríguez Frías F, Esteban R. Buti M, et al. Med Clin (Barc). 2012 Apr 28;138(11):483-8. doi: 10.1016/j.medcli.2011.04.024. Epub 2011 Jun 29. Med Clin (Barc). 2012. PMID: 21719049 Review. Spanish.